Study In Asthma Control

Phase 4

Terminated

• Conditions: Asthma

• Registration Number: NCT00273026
• Lead Sponsor: GlaxoSmithKline

Brief Summary

This study will compare patients treated with a marketed medication and those who continue with their usual care to assess the proportion of patients achieving well controlled asthma after 24 weeks.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2004-11-08
• Study First Submitted: 2006-01-05
• Study First Submitted QC: 2006-01-05
• Study First Posted: 2006-01-09
• Study Completion: 2006-03-28
• Status Verified: 2018-03
• Last Update Submitted: 2018-03-19
• Last Update Posted: 2018-03-21

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 680

Inclusion Criteria

• documented clinical history of asthma and receiving regular maintenance therapy.

Read More

Exclusion Criteria

• Using oral/parenteral or depot corticosteroids within 12 weeks of visit 1.
• History of heavy smoking or substance abuse.
• Females who are pregnant or lactating.
• Required emergency room treatment for their asthma 12 weeks prior to Visit 1.
• Serious, uncontrolled, systemic disease that may make study participation unsafe or inappropriate in the opinion of the physician.
• Other medical criteria will be evaluated at the screening visit.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Percentage of patients achieving well-controlled asthma at the end of the treatment period.

Secondary Outcome Measures

Name	Time	Method
Percentage of patients achieving total asthma control as defined by the Canadian Asthma consensus guidelines at the end of the treatment period.

Trial Locations

Locations (1)

GSK Investigational Site; 🇨🇦 Québec, Canada